3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
8
Ovarian Neoplasms
5
Mesothelioma, Malignant
4
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Neoplasms
2
Mesothelioma
2
Melanoma
2
Glioblastoma
2
Uveal Melanoma
1
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Phase IB
1
Non Hematologic Cancers
1
Neoplasms, Mesothelial
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesonephric Gynecologic Cancer
1
Lymphoma
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Cancer
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
155
Gemcitabine
139
Capecitabine
121
Paclitaxel
118
Fluorouracil
116
Oxaliplatin
110
Bevacizumab
104
Nivolumab
97
Leucovorin
97
Docetaxel
92
Cisplatin
89
Irinotecan
87
Carboplatin
84
Radiosurgery
83
Cyclophosphamide
70
Cetuximab
70
Magnetic Resonance Spectroscopy
68
Trastuzumab
56
Specimen Handling
56
Biopsy
56
Radiotherapy
55
Ipilimumab
52
Everolimus
48
Pemetrexed
46
Drug Therapy
45
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
43
Doxorubicin
41
Fulvestrant
38
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm Metastasis
×
defactinib
×
Clear all
NCT05669482
2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2
Active not recruiting
40 enrolled